Aardvark Therapeutics (AARD) Cash from Financing Activities (2024 - 2026)
Aardvark Therapeutics (AARD) posted Cash from Financing Activities of $4000.0 for Q1 2026, down 98.54% sequentially from $274000.0 in Q4 2025, and down 100.0% YoY from $88.9 million in Q1 2025.
Aardvark Therapeutics (AARD) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Cash from Financing Activities for 3 years, with the latest figure at $4000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 100.0% year-over-year to $4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $378000.0 (down 99.78% YoY) and the FY2025 annual result came in at $89.2 million, up 8.85% from the prior year.
- Cash from Financing Activities fell to $4000.0 in Q1 2026 per AARD's latest filing, from $274000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $88.9 million in Q1 2025 and troughed at -$1.0 million in Q4 2024.
- A 3-year average of $21.4 million and a median of $117500.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 167.19% in 2025, down 100.09% in 2025.
- Over 3 years, Cash from Financing Activities stood at -$1.0 million in 2024, then jumped by 127.02% to $274000.0 in 2025, then slumped by 98.54% to $4000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $4000.0, $274000.0, and $171000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 262,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262,000.00 |
| Jun 30, 2026 | 262,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | 274,000.00 |
| Dec 31, 2025 | 274,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | 88.88 Mn |
| Mar 31, 2025 | 88.88 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | 64,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 82.94 Mn |
| Jun 30, 2024 | 82.94 Mn |